8. Referencias

  1. Global tuberculosis report 2021. Ginebra: Organización Mundial de la Salud; 2021 (https://apps.who.int/iris/handle/10665/346387, consultado el 1 de diciembre del 2021).
  2. Snow KJ, Sismanidis C, Denholm J, et al. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J. 20 18;51(2):1702352.
  3. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Ginebra: Organización Mundial de la Salud; 2022 (https://apps.who.int/iris/bitstream/handle/10665/352522/9789240046764-eng.pdf ).
  4. Marais B. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392–402.
  5. Hoja de ruta para poner fin a la tuberculosis en niños y adolescentes. Washington, D.C.: Organización Panamericana de la Salud; 2020 (https://iris.paho.org/bitstream/handle/10665.2/52187/9789275321348spa.pdf?sequence=1&isAllowed=y, consultado el 1 de diciembre del 2021).
  6. Guidance for national tuberculosis programmes on the management of tuberculosis in children, second edition. Ginebra: Organización Mundial de la Salud; 2014 (https://apps.who.int/iris/handle/10665/112360, consultado el 1 de diciembre del 2021).
  7. The End TB Strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Ginebra: Organización Mundial de la Salud; 2014 (https://apps.who.int/iris/handle/10665/162760, consultado el 1 de diciembre del 2021).
  8. La Agenda para el Desarrollo Sostenible. Nueva York: Naciones Unidas (https://www.un.org/sustainabledevelopment/es/development-agenda/, consultado el 1 de diciembre del 2021).
  9. Declaración política de la reunión de alto nivel de la Asamblea General sobre la lucha contra la tuberculosis. Nueva York: Naciones Unidas; 2018 (https://documents-dds-ny.un.org/doc/UNDOC/GEN/N18/315/57/pdf/ N1831557.pdf?OpenElement, consultado el 1 de diciembre del 2021).
  10. Houben R, Lalli M, Kranzer K, et al. What if they don’t have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis. Clin Infect Dis. 2019;68(1):150–156.
  11. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014;2(8):e453–e459.
  12. Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16(10):1193–1201.
  13. Manual operativo de la OMS sobre la tuberculosis. Módulo 2: Tamizaje. Tamizaje sistemático de la tuberculosis. Washington, D.C.: Organización Panamericana de la Salud; 2022 https://iris.paho.org/bitstream/handle/10665.2/56669/9789275326220_spa.pdf?sequence=1&isAllowed=y).
  14. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 2: Tamizaje. Tamizaje sistemático de la tuberculosis. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://www.paho.org/es/documentos/directrices-unificadas-oms-sobre-tuberculosis-modulo-2-tamizaje-tamizaje-sistematico).
  15. Manual operativo de la OMS sobre la tuberculosis. Módulo 1: Prevención. Tratamiento preventivo de la tuberculosis. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/55801).
  16. Martinez L, Cords O, Horsburgh CR, et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973–984.
  17. Dodd PJ, Yuen CM, Sismanidis C, et al. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5(9):e898-e906.
  18. Gupta A, Swindells S, Kim S, et al. Feasibility of identifying household contacts of rifampin- and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020;70(3):425–435.
  19. Lung T, Marks GB, Nhung NV, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–e384.
  20. Sulis G, Combary A, Getahun H, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Org. 2018;96(6):386–392.
  21. Kay AW, Sandoval M, Mtetwa G, et al. Vikela Ekhaya: a novel, community-based, tuberculosis contact management program in a high burden setting. Clin Infect Dis. 2021; (https://doi.org/10.1093/cid/ciab652, consultado el 1 de diciembre del 2021).
  22. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Ginebra: Organización Mundial de la Salud; 2012 (https://apps.who.int/iris/handle/10665/77741, consultado el 1 de diciembre del 2021).
  23. Padyana M, Bhat RV, Dinesha M, Nawaz A. HIV-tuberculosis: a study of chest X-ray patterns in relation to CD4 count. N Am J Med Sci. 2012;4(5):221–225.
  24. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995;96(1 Pt 1):29–35.
  25. Vonasek B, Ness T, Takwoingi Y, et al. Screening tests for active pulmonary tuberculosis in children. Cochrane Database Syst Rev. 2021;6(6):CD013693.
  26. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 3: Diagnóstico. Diagnóstico rápido para la detección de la tuberculosis. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/55926, consultado el 1 de diciembre del 2021).
  27. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement. Ginebra: Organización Mundial de la Salud; 2011 (https://apps.who.int/iris/handle/10665/44759, consultado el 1 de diciembre del 2021).
  28. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 1: Prevención. Tratamiento preventivo de la tuberculosis. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/55801, consultado el 1 de diciembre del 2021).
  29. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta- analysis of the published literature. JAMA. 1994;271(9):698–702.
  30. Blok L, Sahu S, Creswell J, et al. Comparative meta-analysis of tuberculosis contact investigation interventions in eleven high burden countries. PLoS One. 2015;10(3):e0119822.
  31. BCG vaccines: WHO position paper – February 2018. Ginebra: Organización Mundial de la Salud: 2018 (https://apps.who.int/iris/handle/10665/260307, consultado el 1 de diciembre del 2021).
  32. Prentice S, Nassanga B, Webb EL, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis. 2021;21(7):993–1003.
  33. Information sheet: observed rate of vaccine reactions – bacille Calmette-Guérin (BCG) vaccine. Ginebra: Organización Mundial de la Salud; 2012.
  34. Hesseling AC, Johnson LF, Jaspan H, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ. 2009;87(7):505–511.
  35. Cuello-Garcia CA, Perez-Gaxiola G, Jimenez Gutierrez C. Treating BCG-induced disease in children. Cochrane Database Syst Rev. 2013;(1):CD008300.
  36. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42(4):548–558.
  37. Venkataraman A, Yusuff M, Liebeschuetz S, et al. Management and outcome of Bacille Calmette-Guerin vaccine adverse reactions. Vaccine. 2015;33(41):5470–5474.
  38. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395(10236):1545–1546.
  39. Fritschi N, Curtis N, Ritz N. Bacille Calmette Guerin (BCG) and new TB vaccines: specific, cross-mycobacterial and off-target effects. Paediatr Respir Rev. 2020;36:57–64.
  40. Marais BJ, Seddon JA, Detjen AK, et al. Interrupted BCG vaccination is a major threat to global child health. Lancet Respir Med. 2016;4(4):251–253.
  41. Kontturi A, Santiago B, Tebruegge M, et al. The impact of Bacille Calmette-Guérin shortage on immunisation practice and policies in Europe: a Paediatric Tuberculosis Network European Trials Group (ptbnet) survey. Tuberculosis (Edinb). 2016;101:125–129.
  42. Du Preez K, Seddon JA, Schaaf HS, et al. Global shortages of BCG vaccine and tuberculous meningitis in children. Lancet Glob Health. 2019;7(1):e28–e29.
  43. Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette-Guerin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine. 2018;36(4):498–506.
  44. Global market study: BCG vaccine. Ginebra: Organización Mundial de la Salud; 2019 (consultado el 1 de diciembre del 2021).
  45. Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief – 12 April 2020. Ginebra: Organización Mundial de la Salud; 2020 (https://apps.who.int/iris/handle/10665/331745, consultado el 1 de diciembre del 2021).
  46. Dodd PJ, Prendergast AJ, Beecroft C, et al. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax. 2017;72(6):559–575.
  47. Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.
  48. Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–e1089.
  49. Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Ginebra: Organización Mundial de la Salud; 2011 (https://apps.who.int/iris/handle/10665/44472, consultado el 1 de diciembre del 2021).
  50. Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond). 2017;49(3):161–169.
  51. Cotton MF, Schaaf HS, Lottering G, et al. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–227.
  52. Cranmer LM, Kanyugo M, Jonnalagadda SR, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants. Pediatr Infect Dis J. 2014;33(4):401–406.
  53. Kali PB, Gray GE, Violari A, et al. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr. 2006;42(3):379–381.
  54. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. Aids. 1999;13(14):1899–1904.
  55. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–1847.
  56. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–1144.
  57. Crampin AC, Mwaungulu JN, Mwaungulu FD, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–426.
  58. Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
  59. Chaisson RE, Churchyard GJ. Recurrent tuberculosis: relapse, reinfection, and HIV. J Infect Dis. 2010;201(5):653–655.
  60. Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. En: Kayembe J-M, editor. Tuberculosis. Londres: IntechOpen; 2018 (consultado el 1 de diciembre del 2021).
  61. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Ginebra: Organización Mundial de la Salud; 2018 (https://apps.who.int/iris/handle/10665/260233, consultado el 8 de marzo del 2022).
  62. TB elimination: interferon-gamma release assays (IGRAs) – blood tests for TB infection. Atlanta, Georgia: Centros para el Control y la Prevención de Enfermedades (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, consultado el 1 de diciembre del 2021).
  63. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–2135.
  64. Salgame P, Geadas C, Collins L, et al. Latent tuberculosis infection: revisiting and revising concepts. Tuberculosis (Edinb). 2015;95(4):373–384.
  65. Schwoebel V, Koura KG, Adjobimey M, et al. Tuberculosis contact investigation and short-course preventive therapy among young children in Africa. Int J Tuberc Lung Dis. 2020;24(4):452–460.
  66. Report of the meeting to review the paediatric antituberculosis drug optimization priority list. Ginebra: Organización Mundial de la Salud; 2021 (https://apps.who.int/iris/handle/10665/340316, consultado el 1 de diciembre del 2021).
  67. Becerra MC, Huang C-C, Lecca L, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
  68. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–1677.
  69. Manual para usar las tecnologías digitales en apoyo de la adhesión a la medicación contra la tuberculosis. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/55815, consultado el 1 de diciembre del 2021).
  70. WHO guidelines on tuberculosis infection prevention and control, 2019 update. Ginebra: Organización Mundial de la Salud; 2019 (https://apps.who.int/iris/handle/10665/311259, consultado el 1 de diciembre del 2021).
  71. Definiciones y marco de trabajo para la notificación de tuberculosis – revisión 2013. Ginebra: Organización Mundial de la Salud; 2013 (https://apps.who.int/iris/handle/10665/111016, consultado el 3 de diciembre del 2021).
  72. The Union’s desk guide for diagnosis and management of TB in children, third edition. París: Unión Internacional contra la Tuberculosis y las Enfermedades Pulmonares; 2016 (consultado el 3 de diciembre del 2021).
  73. Kay AW, Gonzalez Fernandez L, Takwoingi Y, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020;8:CD013359.
  74. Jasumback CL, Dlamini Q, Kahari J, et al. Laboratory comparison of stool processing methods for Xpert ® Ultra. Public Health Action. 2021;11(2):55–57.
  75. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis. 2012;55(8):1088–1095.
  76. Organización Panamericana de la Salud. Manual operativo de la OMS sobre la tuberculosis. Módulo 3: Diagnóstico. Métodos de diagnóstico rápido para detectar la tuberculosis. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/55927, consultado el 1 de diciembre del 2021).
  77. Package of care for children and adolescents with advanced HIV disease: stop AIDS. Ginebra: Organización Mundial de la Salud; 2020 (https://apps.who.int/iris/handle/10665/332907, consultado el 6 de diciembre del 2021).
  78. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Ginebra: Organización Mundial de la Salud; 2021 (https://apps.who.int/iris/handle/10665/342899, consultado el 1 de diciembre del 2021).
  79. Fry SH, Barnabas SL, Cotton MF. Tuberculosis and HIV: an update on the “cursed duet” in children. Front Pediatr. 2019;7:159.
  80. Integrated Management of Childhood Illness: chart booklet. Ginebra: Organización Mundial de la Salud; 2014 (https://apps.who.int/iris/handle/10665/104772, consultado el 1 de diciembre del 2021).
  81. Updated guideline: paediatric emergency triage, assessment and treatment – care of critically ill children. Ginebra: Organización Mundial de la Salud; 2016 (https://apps.who.int/iris/handle/10665/204463, consultado el 8 de marzo del 2022).
  82. Manual operativo de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/55997).
  83. Chiang SS, Brooks MB, Jenkins HE, et al. Concordance of drug-resistance profiles between persons with drug-resistant tuberculosis and their household contacts: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(2):250–263.
  84. Management of drug-resistant tuberculosis in children: a field guide. Boston, Massachusetts: Sentinel Project for Pediatric Drug-Resistant Tuberculosis; 2019 (http://sentinel-project.org/wp-ontent/uploads/2019/02/Updated_DRTB-Field-Guide-2019-V3.pdf, consultado el 2 de diciembre del 2021).
  85. Jenkins HE, Yuen CM, Rodriguez CA, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(3):285–295.
  86. Turkova A, Wills GA, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med. 2022;386(7).
  87. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/56062)
  88. Graham SM, Grzemska M, Gie RP. The background and rationale for a new fixed-dose combination for first- line treatment of tuberculosis in children. Int J Tuberc Lung Dis. 2015;19(Suppl 1):3–8.
  89. Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis. 2006;10(12):1318–1330.
  90. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Ginebra: Organización Mundial de la Salud; 2007 (https://apps.who.int/iris/handle/10665/43699, consultado el 6 de diciembre del 2021).
  91. Directriz: actualizaciones sobre la atención de la desnutrición aguda severa en lactantes y niños. Ginebra: Organización Mundial de la Salud; 2013 (https://apps.who.int/iris/handle/10665/249206, consultado el 8 de marzo del 2022).
  92. Schaaf HS, Marais BJ, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis. 2007;7(1):140.
  93. Wolzak NK, Cooke ML, Orth H, van Toorn R. The changing profile of pediatric meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr. 2012;58(6):491–495.
  94. Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):947–957.
  95. Van Toorn R, Schaaf HS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33(3):248–252.
  96. Van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123(1):e1–e8.
  97. Rapid advice: treatment of tuberculosis in children. Ginebra: Organización Mundial de la Salud; 2010 (https://apps.who.int/iris/handle/10665/44444, consultado el 8 de marzo del 2022).
  98. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis (Edinb). 2010;90(6):375–392.
  99. Guidelines for the management of tuberculosis in children. Pretoria: Department of Health; 2013 (www. kznhealth.gov.za/family/National-Childhood-TB-Guidelines-2013-ZA.pdf, consultado el 11 de marzo del 2022).
  100. Statement on the use of child-friendly fixed-dose combinations for the treatment of TB in children. Ginebra: Organización Mundial de la Salud y Fondo de las Naciones Unidas para la Infancia; 2017 (consultado el 11 de marzo del 2022).
  101. New pathways for childhood TB treatment: lessons from the STEP-TB Project. New York and Vernier: TB Alliance and Unitaid; 2017 (https://www.tballiance.org/sites/default/files/child-resources/New_Pathways_for_Childhood_TB_Treatment.pdf, consultado el 6 de diciembre del 2021).
  102. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4(4):CD002244.
  103. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–231.
  104. Essential nutrition actions: mainstreaming nutrition through the life-course. Ginebra: Organización Mundial de la Salud; 2019 (https://apps.who.int/iris/handle/10665/326261, consultado el 8 de marzo del 2022).
  105. Guideline: nutritional care and support for patients with tuberculosis. Ginebra: Organización Mundial de la Salud; 2013 (https://apps.who.int/iris/handle/10665/94836, consultado el 6 de diciembre del 2021).
  106. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
  107. Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. Ginebra: Organización Mundial de la Salud; 2017 (https://apps.who.int/iris/handle/10665/255052, consultado el 8 de marzo del 2022).
  108. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020. Ginebra: Organización Mundial de la Salud; 2021 (https://apps.who.int/iris/handle/10665/340284, consultado el 6 de diciembre del 2021).
  109. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195.
  110. Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383(9928):1572–1579.
  111. Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e1002591.
  112. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69(5):458–464.
  113. Shah NS, Yuen CM, Heo M, et al. Yield of contact investigations in households of patients with drug- resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):381–391.
  114. Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449–456.
  115. Gegia M, Jenkins HE, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009–2011. Int J Tuberc Lung Dis. 2013;17(5):624–629.
  116. Directrices unificadas de la OMS sobre la tuberculosis. Módulo 4: Tratamiento. Tratamiento de la tuberculosis farmacorresistente. Washington, D.C.: Organización Panamericana de la Salud; 2022 (https://iris.paho.org/handle/10665.2/56062).
  117. Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021;21(7):975–983.
  118. Svensson EM, Aweeka F, Park JG, et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2780–2787.
  119. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58(11):6406–6412.
  120. Brill MJ, Svensson EM, Pandie M, et al. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49(2):212–217.
  121. Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug–drug interactions in healthy subjects. Antimicrob Agents Chemother. 2016;60(10):5976–5985.
  122. StopTB Partnership Global Drug Facility Paediatric Drug-Resistant TB (DR-TB) Donation Initiative [página web]. Boston: Sentinel Project on Pediatric Drug-Resistant Tuberculosis; 2019 (http://sentinel-project.org/2019/02/18/stoptbgdfs-paediatric-drug-resistant-tb-dr-tb-donation-initiative/, consultado el 16 de marzo del 2022).
  123. Svensson EM, du Bois J, Kitshoff R, et al. Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children. Br J Clin Pharmacol. 2018;84(10):2384-2392.
  124. Schaaf HS, Thee S, van der Laan L, et al. Adverse effects of oral second-line antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15(10):1369–1381.
  125. Garcia-Prats AJ, Schaaf HS, Hesseling AC. The safety and tolerability of the second-line injectable antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15(11):1491–1500.
  126. Schaaf HS, Garcia-Prats AJ, McKenna L, Seddon JA. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Rev Clin Pharmacol. 2018;11(3):233–244.
  127. Garcia-Prats AJ, Schaaf HS, Draper HR, et al. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies. PLoS Med. 2019;16(4):e1002789.
  128. Isaakidis P, Paryani R, Khan S, et al. Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India. PLoS One. 2013;8(7):e68869.
  129. Moyo S, Furin JJ, Hughes J, et al. Outcomes in adolescents undergoing treatment for drug-resistant tuberculosis in Cape Town, South Africa, 2008–2013. Arch Pediatr Infect Dis. 2015;3(1 TB):e17934.
  130. A family-centered approach to the treatment and prevention of drug-resistant tuberculosis in children and adolescents: Counselling tools and approach. Khayelitsha: Medecins Sans Frontieres; 2021 (http://sentinel-project.org/wp-content/uploads/2021/12/Peds_Counseling_Outline_V3.pdf, consultado el 12 de marzo del 2022).
  131. Allwood BW, Byrne A, Meghji J, et al. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration. 2021;100(8):751–763.
  132. Allwood BW, Amaral AFS, Byrne A, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis. 2020;24(8):820–828.
  133. Dodd PJ, Yuen CM, Jayasooriya SM, et al. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis. 2021;21(7):984–992.
  134. Schoeman J, Wait J, Burger M, et al. Long-term follow up of childhood tuberculous meningitis. Dev Med Child Neurol. 2002;44(8):522–526.
  135. Gupta R, Kushwaha S, Thakur R, et al. Predictors of adverse outcome in patients of tuberculous meningitis in a multi-centric study from India. Indian J Tuberc. 2017;64(4):296–301.
  136. Dhawan SR, Gupta A, Singhi P, et al. Predictors of neurological outcome of tuberculous meningitis in childhood: a prospective cohort study from a developing country. J Child Neurol. 2016;31(14):1622–1627.
  137. Davis AG, Nightingale S, Springer PE, et al. Neurocognitive and functional impairment in adult and paediatric tuberculous meningitis. Wellcome Open Res. 2019;4:178.
  138. Dian S, Hermawan R, van Laarhoven A, et al. Brain MRI findings in relation to clinical characteristics and outcome of tuberculous meningitis. PLoS One. 15(11): e0241974.
  139. Garg RK, Malhotra HS, Kumar N, Uniyal R. Vision loss in tuberculous meningitis. J Neurol Sci. 2017;375:27–34.
  140. Lam KS, Sham MM, Tam SC, et al. Hypopituitarism after tuberculous meningitis in childhood. Ann Intern Med. 1993;118(9):701–706.
  141. Osman M, Welte A, Dunbar R, et al. Morbidity and mortality up to 5 years post tuberculosis treatment in South Africa: a pilot study. 2019. Int J Infect Dis. 2019;85:57–63.
  142. Basham CA, Romanowski K, Johnston JC. Life after tuberculosis: planning for health. Lancet Respir Med. 2019;7(12):1004–1006.
  143. Romanowski K, Baumann B, Basham CA, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(10):1129-1137.
  144. Marx FM, Cohen T, Menzies NA, et al. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. Lancet Glob Health. 2020;8(9):e1223–e1233.
  145. Marx FM, Yaesoubi R, Menzies NA, et al. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. Lancet Glob Health. 2018;6(4):e426–e435.
  146. Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007;175(12):1304–1345.
  147. Guillien A, Soumagne T, Regnard J, Degano B. Les nouvelles équations de référence du Global Lung Function Initiative (GLI) pour les explorations fonctionnelles respiratoires. [The new reference equations of the Global Lung function Initiative (GLI) for pulmonary function tests.] Rev Mal Respir. 2018;35(10):1020–1027.
  148. Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021;58(2):2002990.
  149. Shah I, Dani S, Shetty NS, et al. Profile of osteoarticular tuberculosis in children. Indian J Tuberc. 2020;67(1):43–45.
  150. Rajasekaran S. Natural history of Pott’s kyphosis. Eur Spine J. 2013;22(Suppl 4):634–640.
  151. Mann TN, Schaaf HS, Dunn RN, et al. Child and adult spinal tuberculosis at tertiary hospitals in the Western Cape, South Africa: 4-year burden and trend. Epidemiol Infect. 2018;146(16):2107–2115.
  152. Dhammi I, Kumar S. Current concepts in diagnosis and management of osteoarticular tuberculosis. Orthop J M P. 2020;26(1):3–13.
  153. Germain N, Aballéa S, Toumi M. Measuring health-related quality of life in young children: how far have we come? [Published correction appears in J Mark Access Health Policy. 2019;11;7(1):1626572.] J Mark Access Health Policy. 2019;7(1):1618661.
  154. Verstraete J, Ramma L, Jelsma J. Item generation for a proxy health related quality of life measure in very young children. Health Qual Life Outcomes. 2020;18(1):11.
  155. Wille N, Badia X, Bonsel G, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875–886.
  156. Verstraete J, Lloyd A, Scott D, Jelsma J. How does the EQ-5D-Y Proxy version 1 perform in 3, 4 and 5-year- old children? Health Qual Life Outcomes. 2020;18:149.
  157. Graham SM, Sekadde MP. Case detection and diagnosis of tuberculosis in primary-care settings. Paediatr Int Child Health. 2019;39(2):84–87.
  158. Dongo JP, Graham SM, Nsonga J, et al. Implementation of an effective decentralised programme for detection, treatment and prevention of tuberculosis in children. Trop Med Infect Dis. 2021;6(3).
  159. Talukder K, Salim MA, Jerin I, et al. Intervention to increase detection of childhood tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2012;16(1):70–75.
  160. Ketema L, Dememew ZG, Assefa D, et al. Evaluating the integration of tuberculosis screening and contact investigation in tuberculosis clinics in Ethiopia: a mixed method study. PLoS One. 2020;15(11):e0241977.
  161. Maha A, Majumdar SS, Main S, et al. The effects of decentralisation of tuberculosis services in the East New Britain Province, Papua New Guinea. Publ Health Act. 2019;9(Suppl 1):S43-S49.
  162. Multisectoral accountability framework to accelerate progress to end tuberculosis by 2030. Ginebra: Organización Mundial de la Salud; 2019 (https://apps.who.int/iris/handle/10665/331934, consultado el 1 de diciembre del 2021).
  163. Marco de Rendición de Cuentas Multisectorial de la OMS para la TB (MRC-TB): Lista de verificación de evaluación inicial, para uso de los países con miras al establecimiento de un MRC-TB nacional. Ginebra: Organización Mundial de la Salud; 2020 (https://cdn.who.int/media/docs/default-source/hq-tuberculosis/who_maftb_checklist_form-final-sp.pdf?sfvrsn=9906158a_3, consultado el 1 de diciembre del 2021).
  164. Progress towards the achievement of global tuberculosis targets and implementation of the political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis: report of the Secretary-General. Nueva York: Asamblea General de las Naciones Unidas; 2020 (https://apps.who.int/iris/handle/10665/343376, consultado el 8 de marzo del 2022).
  165. Zawedde-Muyanja S, Nakanwagi A, Dongo JP, et al. Decentralisation of child tuberculosis services increases case finding and uptake of preventive therapy in Uganda. Int J Tuberc Lung Dis. 2018;22(11):1314–1321.
  166. Khan AJ, Khowaja S, Khan FS, et al. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. Lancet Infect Dis. 2012;12(8):608–616.
  167. Política de la OMS sobre actividades de colaboración TB/VIH : guías para programas nacionales y otros interesados directos. Ginebra: Organización Mundial de la Salud; 2012 (https://apps.who.int/iris/handle/10665/44838, consultado el 1 de diciembre del 2021).
  168. Standards for improving the quality of care for children and young adolescents in health facilities. Ginebra: Organización Mundial de la Salud; 2018 (https://apps.who.int/iris/handle/10665/272346, consultado el 1 de diciembre del 2021).
  169. Young M, Wolfheim C, Marsh DR, Hammamy D. World Health Organization/United Nations Children’s Fund joint statement on integrated community case management: an equity-focused strategy to improve access to essential treatment services for children. Am J Trop Med Hyg. 2012;87(5 Suppl):6–10.
  170. Marais BJ, Obihara CC, Warren RM, et al. The burden of childhood tuberculosis: a public health perspective. Int J Tuberc Lung Dis. 2005;9(12):1305–1313.
  171. Onazi O, Gidado M, Onazi M, et al. Estimating the cost of TB and its social impact on TB patients and their households. Publ Health Act. 2015;5(2):127–131.
  172. Goyal-Honavar A, Markose AP, Chhakchhuakk L, et al. Unmasking the human face of TB: the impact of tuberculosis on the families of patients. J Fam Med Prim Care. 2020;9(10):5345–5350.
  173. Best practices in child and adolescent tuberculosis care. Ginebra: Organización Mundial de la Salud; 2018 (https://apps.who.int/iris/handle/10665/274373, consultado el 1 de diciembre del 2021).
  174. Public–private mix for TB prevention and care: a roadmap. Ginebra: Organización Mundial de la Salud; 2018 (https://apps.who.int/iris/handle/10665/333885, consultado el 1 de diciembre del 2021).
  175. Stallworthy G, Dias HM, Pai M. Quality of tuberculosis care in the private health sector. J Clin Tuberc Other Mycobact Dis. 2020;20:100171.
  176. Uplekar M, Juvekar S, Morankar S, et al. Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis. 1998;2(4):324–329.
  177. Integrating intensive TB case finding and TB preventive treatment services into differentiated ART models: framework for implementation. Nueva York: CQUIN TB/HIV Community of Practice; 2019 (https://cquin.icap.columbia.edu/wp-content/uploads/2020/01/CQUIN-TPT-Toolkit_Jan-2020_Final_Cover.pdf, consultado el 1 de diciembre del 2021).
  178. Mantenimiento de los servicios de salud esenciales: orientaciones operativas en el contexto de la COVID-19: orientaciones provisionales, 1 de junio de 2020. Ginebra: Organización Mundial de la Salud; 2020 (https:// apps.who.int/iris/handle/10665/334360, consultado el 3 de diciembre del 2021).
  179. WHO information note: COVID-19 – considerations for tuberculosis (TB) care. Ginebra: Organización Mundial de la Salud; 2021 (https://apps.who.int/iris/handle/10665/341126, consultado el 1 de diciembre del 2021).
  180. Briefing note: testing for both tuberculosis and SARS-CoV-2. Ginebra: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2021 (https://www.theglobalfund.org/media/11438/covid19_tb-testing_briefingnote_en.pdf, consultado el 3 de diciembre del 2021).
  181. Cerrone M, Wang X, Neary M, et al. Pharmacokinetics of efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2019;68(3):446–452.
  182. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21–27.
  183. Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020;70(4):549–556.
  184. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009;30(4):797–810.
  185. Link-Gelles R, Moultrie H, Sawry S, et al. Tuberculosis immune reconstitution inflammatory syndrome in children initiating antiretroviral therapy for HIV infection: a systematic literature review. Pediatr Infect Dis J. 2014;33(5):499–503.
  186. Rabie H, Violari A, Duong T, et al. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011;15(9):1194-i.
  187. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532–1549.
  188. Jonsson J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden. Eur Respir J. 2020;55(3).
  189. Tuberculosis in women. Ginebra: Organización Mundial de la Salud; 2015 (consultado el 6 de diciembre del 2021).
  190. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy. 2012;2012:379271.
  191. Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–249.
  192. Gupta A, Bhosale R, Kinikar A, et al. Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2011;203(3):358–363.
  193. Gomes VF, Andersen A, Wejse C, et al. Impact of tuberculosis exposure at home on mortality in children under 5 years of age in Guinea-Bissau. Thorax. 2011;66(2):163–167.
  194. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185(7):779–784.
  195. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health. 2014;2(12):e710–e716.
  196. Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials. 2018;19(1):237.
  197. Resolución WHA67.19. Fortalecimiento de los cuidados paliativos como parte del tratamiento integral a lo largo de la vida. Ginebra: Organización Mundial de la Salud; 2014 (https://apps.who.int/gb/ebwha/pdf_ files/WHA67/A67_R19-sp.pdf, consultado el 6 de diciembre del 2021).
  198. Global atlas of palliative care, 2nd edition. Londres: Worldwide Palliative Care Alliance; 2020 (http://www.thewhpca.org/resources/global-atlas-on-end-of-life-care, consultado el 6 de diciembre del 2021).
  199. Connor SR. Palliative care for tuberculosis. J Pain Symptom Manage. 2018;55(2S):S178–S180.
  200. Connor S, Foley K, Harding R, Jaramillo E. Declaration on palliative care and MDR/XDR-TB. Int J Tuberc Lung Dis. 2012;16(6):712–713.
  201. USAID/TB CARE II Project. Comprehensive guidelines for TB and DR-TB palliative care and support. Bethesda, MD: University Research Co., LLC. (http://www.thewhpca.org/resources/item/south-african- palliative-care-guidelines-for-tb, consultado el 8 de marzo del 2022.
  202. Clinical practice guidelines for providing palliative care to patients with tuberculosis. Biskek: Ministerio de Salud de Kirguistán; 2014 (consultado el 6 de diciembre del 2021).
  203. Integrating palliative care and symptom relief into paediatrics: a WHO guide for health care planners, implementers and managers. Ginebra: Organización Mundial de la Salud; 2018 (https://apps.who.int/iris/handle/10665/274561, consultado el 6 de diciembre del 2021).
  204. Policy brief: palliative care for children with drug-resistant tuberculosis. Bristol: International Children’s Palliative Care Network; 2013 (http://www.riatt-esa.org/s/Policy-Brief-on-Palliative-Care-for-Children-with- Durg-Resistant-TUberculosis-DR-TB.pdf, consultado el 6 de diciembre del 2021).
  205. Palliative care for children with drug-resistant TB: an ICPCN position paper. Bristol: International children’s palliative care network; 2013 (https://www.icpcn.org/wp-content/uploads/2013/07/ICPCN-Position-paper- on-Drug-Resistant-TB.pdf, consultado el 6 de diciembre del 2021).
  206. Assessing the development of palliative care worldwide: a set of actionable indicators. Ginebra: Organización Mundial de la Salud; 2021 (https://apps.who.int/iris/handle/10665/345532, consultado el 6 de diciembre del 2021).
  207. Craig F, Henderson EM, Bluebond-Langner M. Management of respiratory symptoms in paediatric palliative care. Curr Opin Support Palliat Care. 2015;9(3):217–226.
  208. Ringholz F, Devins M, McNally P. Managing end stage lung disease in children. Paediatr Respir Rev. 2014;15(1):75–80.
  209. Ross DA, Hinton R, Melles-Brewer M, et al. Adolescent well-being: a definition and conceptual framework. J Adolesc Health. 2020;67(4):472–476.
  210. Kay AW, Thivalapill N, Skinner D, et al. Predictors of suboptimal adherence to isoniazid preventive therapy among adolescents and children living with HIV. PLoS One. 2020;15(12):e0243713.
  211. Hovell M, Blumberg E, Gil-Trejo L, et al. Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis. Soc Sci Med. 2003;56(8):1789–1796.
  212. Kam A, Ford-Jones L, Malloy P, et al. Active tuberculosis among adolescents in Toronto, Canada: clinical features and delays in diagnosis. Pediatr Infect Dis J. 2007;26(4):355–356.
  213. Nduba V, Hoog AH, Mitchell E, et al. Prevalence of tuberculosis in adolescents, western Kenya: implications for control programs. Int J Infect Dis. 2015;35:11–17.
  214. Enane LA, Lowenthal ED, Arscott-Mills T, et al. Loss to follow-up among adolescents with tuberculosis in Gaborone, Botswana. Int J Tuberc Lung Dis. 2016;20(10):1320–1325.
  215. Mulongeni P, Hermans S, Caldwell J, et al. HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. PloS One. 2019;14(2):e0210937.
  216. Enane LA, Eby J, Arscott-Mills T, et al. TB and TB-HIV care for adolescents and young adults. Int J Tuberc Lung Dis. 2020;24(2):240–249.
  217. Guix-Comellas E-M, Rozas L, Velasco-Arnaiz E, et al. Adherence to antituberculosis drugs in children and adolescents in a low-endemic setting: a retrospective series. Pediat Infect Dis J. 2017;36(6):616–618.
  218. De Oliveira MCB, Sant’Anna CC, Raggio Luiz R, Kritski AL. Unfavorable outcomes in tuberculosis: multidimensional factors among adolescents in Rio de Janeiro, Brazil. Am J Trop Med Hyg. 2020;103(6):2492–2500.
  219. Reif LK, Rivera V, Bertrand R, et al. Outcomes across the tuberculosis care continuum among adolescents in Haiti. Publ Health Act. 2018;8(3):103–109.
  220. Laycock KM, Eby J, Arscott-Mills T, et al. Towards quality adolescent-friendly services in TB care. Int J Tuberc Lung Dis. 2021;25(7):579–583.
  221. Making health services adolescent friendly: developing national quality standards for adolescent friendly health services. Ginebra: Organización Mundial de la Salud; 2012 (https://apps.who.int/iris/handle/10665/75217, consultado el 6 de diciembre del 2021).
  222. Aceleración mundial de las medidas para promover la salud de los adolescentes (Guía AA-HA!): Orientación para la aplicación en los países. Washington, D.C.: Organización Panamericana de la Salud; 2018 (https://iris.paho.org/handle/10665.2/49181, consultado el 6 de diciembre del 2021).
  223. Kazi S, Corcoran H, Abo Y-N, for the ARI Review group. A systematic review of clinical, epidemiological and demographic predictors of tuberculosis in children with pneumonia. J Glob Health (en imprenta). 2022.
  224. O’Brien KL, Baggett HC, Brooks WA, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394(10200):757–779.
  225. Vessière A, Font H, Gabillard D, et al. Impact of systematic early tuberculosis detection using Xpert MTB/ RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial. BMC Pediatrics. 2021;21(1):136.
  226. Marcy O, Font H, Vessière A, for the TB Speed Pneumonia Study Group. Impact of systematic TB detection using Xpert Ultra on nasopharyngeal aspirates and stool samples on mortality in children with severe pneumonia. Presentation. París: Unión Internacional contra la Tuberculosis y las Enfermedades Pulmonares; 2021.
  227. Results of an international cluster randomized trial on systematic tuberculosis detection in children with severe pneumonia. Bordeaux: TB-SPEED Pneumonia; 2021 (https://www.tb-speed.com/wp-content/uploads/2021/10/TB-Speed_Pneumonia_Study_Press_Release_20211021-.pdf, consultado el 8 de marzo del 2022).
  228. Black RE, Victora CG, Walker SP, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet. 2013;382(9890):427–451.
  229. Patel LN, Detjen AK. Integration of childhood TB into guidelines for the management of acute malnutrition in high burden countries. Public Health Action. 2017;7(2):110–115.
  230. Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. J Infect Dis. 2012;206(12):1809–1815.
     

Book navigation